Zacks Investment Research on MSN3d
How to Play SRPT Stock After Patient Death Post DMD Therapy InfusionShares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
Zacks Investment Research on MSN8d
SRPT Nosedives 27% on Patient Death Following DMD Therapy InfusionShares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
9don MSN
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment ...
The price trend for Sarepta Therapeutics (SRPT) has been bearish lately and the stock has lost 9% over the past four weeks. However, the formation of a hammer chart pattern in its last trading ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...
Shares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following treatment with Elevidys, its one-shot gene therapy for Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback